{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:04:31Z","timestamp":1792757071012,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20ck0106581"],"award-info":[{"award-number":["JP20ck0106581"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.cllc.2021.01.017","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T15:45:51Z","timestamp":1612539951000},"page":"401-410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non\u2013Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab"],"prefix":"10.1016","volume":"22","author":[{"given":"Takashi","family":"Shintani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5007-8808","authenticated-orcid":false,"given":"Noriko","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Mitsuyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setsuko","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Nakamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Narabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5640-7665","authenticated-orcid":false,"given":"Yuichi","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satsuki","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-487X","authenticated-orcid":false,"given":"Tomohiro","family":"Katagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Hak","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8135-8746","authenticated-orcid":false,"given":"Takashi","family":"Mizowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2021.01.017_bib0001","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.chest.2019.03.033","article-title":"Radiation-induced lung injury","volume":"156","author":"Hanania","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.cllc.2021.01.017_bib0002","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1200\/JCO.2009.24.5050","article-title":"Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105","volume":"28","author":"Yamamoto","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2021.01.017_bib0003","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1200\/JCO.2009.24.7577","article-title":"Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007","volume":"28","author":"Segawa","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2021.01.017_bib0004","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/JCO.2015.64.8824","article-title":"PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer","volume":"34","author":"Senan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2021.01.017_bib0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","article-title":"Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial","volume":"35","author":"Chun","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2021.01.017_bib0006","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.radonc.2004.02.015","article-title":"Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer\u2013a systematic review","volume":"71","author":"Rodrigues","year":"2004","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2021.01.017_bib0007","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ijrobp.2012.04.043","article-title":"Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis","volume":"85","author":"Palma","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2021.01.017_bib0008","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/JTO.0000000000000187","article-title":"Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer","volume":"9","author":"Tsujino","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2021.01.017_bib0009","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2021.01.017_bib0010","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2021.01.017_bib0011","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed\u00a0death 1 and programmed death-ligand 1 inhibitors\u00a0in\u00a0non-small cell\u00a0lung\u00a0cancer","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.cllc.2021.01.017_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2018.02.023","article-title":"ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer","volume":"127","author":"Nestle","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2021.01.017_bib0013","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.radonc.2008.09.009","article-title":"Dose\u2013volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy","volume":"91","author":"Jin","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2021.01.017_bib0014","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cllc.2021.01.017_bib0015","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1002\/cam4.3113","article-title":"Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab","volume":"9","author":"Shaverdian","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.cllc.2021.01.017_bib0016","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/1759-7714.13394","article-title":"Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: management of adverse events","volume":"11","author":"Miura","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.cllc.2021.01.017_bib0017","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1007\/s10637-020-00917-2","article-title":"Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer","volume":"38","author":"Inoue","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.cllc.2021.01.017_bib0018","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2020.05.035","article-title":"Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"146","author":"Jung","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2021.01.017_bib0019","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jtho.2017.07.020","article-title":"Thoracic oncology clinical trial eligibility criteria and requirements continue to increase in number and complexity","volume":"12","author":"Garcia","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2021.01.017_bib0020","doi-asserted-by":"crossref","first-page":"S370","DOI":"10.1016\/j.jtho.2018.08.350","article-title":"MA05.02 PACIFIC subgroup analysis: pneumonitis in stage III, unresectable NSCLC patients treated with durvalumab vs. placebo after CRT","volume":"13","author":"Vansteenkiste","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2021.01.017_bib0021","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0360-3016(02)03807-5","article-title":"Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer","volume":"55","author":"Tsujino","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2021.01.017_bib0022","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2020.10.008","article-title":"Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: a real-world multicentre study","volume":"142","author":"Desilets","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2021.01.017_bib0023","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2020.10.006","article-title":"Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): real-world data on survival and safety from the German expanded-access program (EAP)","volume":"150","author":"Faehling","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2021.01.017_bib0024","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1200\/JCO.20.00131","article-title":"Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: CheckMate 153","volume":"38","author":"Waterhouse","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2021.01.017_bib0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.semradonc.2014.11.004","article-title":"Intensity-modulated radiotherapy, not 3 dimensional conformal, is the preferred technique for treating locally advanced disease with high-dose radiotherapy: the argument against","volume":"25","author":"Price","year":"2015","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.cllc.2021.01.017_bib0026","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.semradonc.2014.11.002","article-title":"Intensity-modulated radiotherapy, not 3 dimensional conformal, is the preferred technique for treating locally advanced lung cancer","volume":"25","author":"Chang","year":"2015","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.cllc.2021.01.017_bib0027","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.lungcan.2013.08.015","article-title":"Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: predictors of use and association with toxicities","volume":"82","author":"Shirvani","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2021.01.017_bib0028","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ijrobp.2019.12.027","article-title":"A comparison of radiation techniques in patients treated with concurrent chemoradiation for stage III non-small cell\u00a0lung cancer","volume":"106","author":"Peng","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2021.01.017_bib0029","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.ijrobp.2009.02.032","article-title":"Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy","volume":"76","author":"Liao","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2021.01.017_bib0030","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jtho.2016.09.134","article-title":"Heart dose is an independent dosimetric predictor of overall survival in locally advanced non-small cell lung cancer","volume":"12","author":"Speirs","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2021.01.017_bib0031","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jtho.2019.10.024","article-title":"Phase II trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC","volume":"15","author":"Lin","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2021.01.017_bib0032","first-page":"10","article-title":"Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer","volume":"144","author":"Shaverdian","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2021.01.017_bib0033","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jtho.2019.10.002","article-title":"Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC\u2013update from PACIFIC","volume":"15","author":"Gray","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2021.01.017_bib0034","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.semradonc.2014.12.003","article-title":"Nondosimetric risk factors for radiation-induced lung toxicity","volume":"25","author":"Kong","year":"2015","journal-title":"Semin Radiat Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730421000206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730421000206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:11:22Z","timestamp":1761505882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730421000206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1525730421000206"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2021.01.017","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non\u2013Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2021.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}